Physicians' Academy for Cardiovascular Education

Registry study shows large reduction of clinical outcomes by lipoprotein apheresis

News - June 3, 2021

The German Lipoprotein Apheresis Registry (GLAR) – more than seven years on

Presented at the virtual EAS 2021 by Volker Schettler (Göttingen, Germany)

Introduction and methods

Data from the German Apheresis Registry from 2012-2020 were presented. 83 Apheresis centers participated and more than 2000 patients who underwent lipoprotein apheresis (LA) were enrolled, resulting in 47.685 documented LA treatments. Definition of major coronary events (MACE) was new ACS (STEMI or NSTEMI), new instable angina pectoris or new intervention. In addition, outcome of major non-coronary events (MANCE) was evaluated, including new cerebrovascular disease or diseases that affect the peripheral system.

Main results


An analysis of the GLAR registry showed an impressive decrease of MACE and MANCE within two years of initiation of LA, which was stable throughout the duration of the study. Number of side effects are low and LA is safe. Schettler said at the end that with the arrival of new lipid-lowering therapy (PCSK9 inhibitors or PCSK9 siRNA) number of LA treatment may reduce over the following years, however, this is unsure due to increased attention to severe lipoprotein disorders.

-Our reporting is based upon the information provided at the EAS 2021 congress-

Share this page with your colleagues and friends: